Navigation Links
Rutgers offers hope in new treatment for spinal cord injuries
Date:5/3/2011

Rutgers researchers have developed an innovative new treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing and minimize pain.

After a spinal cord injury there is an increased production of a protein (RhoA) that blocks regeneration of nerve cells that carry signals along the spinal cord and prevents the injured tissue from healing.

Scientists at the W.M. Keck Center for Collaborative Neuroscience and Quark Pharmaceuticals Inc. have developed a chemically synthesized siRNA molecule that decreases the production of the RhoA protein when administered to the spine and allows regeneration of the nerve cells.

"It is exciting because this minimally-invasive treatment can selectively target the injured tissue and thereby promote healing and reduce pain," says Martin Grumet, associate director of the Keck Center and senior author of a recent study published in the Journal of Neurotrauma.

The neuropathic pain, also known as phantom pain that occurs as a result of a spinal cord injury is often associated with an increased production of RhoA. When researchers injected the chemically synthesized molecular substance into the spinal cords of laboratory rats with spinal cord injury using a procedure similar to a spinal tap, there was an overall improvement in tissue healing and recovery.

More than 250,000 people in the United States are living with a spinal cord injury and currently there is no way to reverse the damage. No drugs for early treatment of spinal cord injury have been approved in over a decade. Based on this joint research, Quark Pharmaceuticals, Inc now has a drug development program for the treatment of spinal cord injury and neuropathic pain. This new research is supported by grants from the New Jersey Commission for Spinal Cord Research and Quark.


'/>"/>

Contact: Robin Lally
rlally@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Page: 1

Related biology news :

1. Rutgers scholar authors definitive biography of reproductive medicine pioneer
2. Rutgers receives US$10 million to establish Institute for Food, Nutrition and Health
3. Evolution and climate change research advances at Rutgers-Camden
4. Rutgers study finds many consumers ignore food product recalls
5. Rutgers research tackles childhood epilepsy
6. Rutgers-Camden developing enzyme function database
7. Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI
8. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
9. NSF grant supports Rutgers-Camden program for science majors
10. Rutgers cell biologist pinpoints how RNA viruses copy themselves
11. Rutgers researchers discover secrets of nutritious corn breed that withstands rigors of handling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... -- Partnering to fuel Philadelphia,s innovative ... Southeastern Pennsylvania (" Ben Franklin "); ... Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... million funding initiative over a four year period to ... a burgeoning economic vitality in digital health, Ben ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, ... escalation and expansion clinical trial for its lead drug candidate, AC0010, at the ... the trial was to determine the safety, antitumor activity, and recommended phase II ...
(Date:12/7/2016)... ... 07, 2016 , ... Huffman Engineering, Inc. , a ... Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company recognized ... Integrator Partner certification gives customers confidence that our engineers are fully trained and ...
(Date:12/7/2016)... - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused ... for the treatment of cancer, today announced that ... Program with Cytovance Biologics ( Oklahoma City, ... product. Supported by recent positive interim clinical results ... cancer patients, OncoQuest has engaged Cytovance to establish ...
Breaking Biology Technology: